Physician profile
William E Ervine
NPI 1710936505
$5,983.33
in general payments reported to CMS, 2019-2025
42 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $141 · 2021: $597 · 2022: $863 · 2023: $1,126 · 2024: $1,342 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,167.34 | 2019-2025 | |
| Pfizer INC. | $593.40 | 2019-2025 | |
| Novo Nordisk INC | $445.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $377.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $319.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Axsome Therapeutics, INC. | $256.33 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $248.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.38 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $214.97 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $193.97 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.32 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $175.03 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $151.24 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.59 | 2023-2025 | Caplyta |
| Abbott Laboratories | $128.10 | 2021-2025 | Freestyle Libre 3 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ervine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.